

Rosaria Luciani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7835206/publications.pdf>

Version: 2024-02-01

28
papers

839
citations

471509
17
h-index

501196
28
g-index

28
all docs

28
docs citations

28
times ranked

1462
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. <i>Scientific Reports</i> , 2013, 3, 1035.	3.3	133
2	2-Carboxyquinoxalines Kill <i>Mycobacterium tuberculosis</i> through Noncovalent Inhibition of DprE1. <i>ACS Chemical Biology</i> , 2015, 10, 705-714.	3.4	116
3	Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E542-9.	7.1	77
4	Virtual Screening Identification of Nonfolate Compounds, Including a CNS Drug, as Antiparasitic Agents Inhibiting Pteridine Reductase. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 211-221.	6.4	68
5	Structure-Based Selectivity Optimization of Piperidine-Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8318-8329.	6.4	42
6	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7598-7616.	6.4	41
7	Microbiota of sliced cooked ham packaged in modified atmosphere throughout the shelf life. <i>International Journal of Food Microbiology</i> , 2019, 289, 200-208.	4.7	35
8	Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. <i>European Journal of Pharmacology</i> , 2009, 615, 17-26.	3.5	29
9	The structure of <i>Enterococcus faecalis</i> thymidylate synthase provides clues about folate bacterial metabolism. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2012, 68, 1232-1241.	2.5	28
10	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 423-434.	5.5	27
11	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit <i>Trypanosoma brucei</i> Pteridine Reductase in Support of Early-Stage Drug Discovery. <i>ACS Omega</i> , 2017, 2, 5666-5683.	3.5	24
12	Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1355-1367.	6.4	22
13	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. <i>ChemMedChem</i> , 2016, 11, 1653-1666.	3.2	21
14	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3989-4012.	6.4	21
15	Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 7773-7785.	3.0	20
16	Inhibitor of Ovarian Cancer Cells Growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10272-10276.	6.4	20
17	Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9269-9275.	6.4	19
18	X-ray crystal structures of <i>Enterococcus faecalis</i> thymidylate synthase with folate binding site inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 649-664.	5.5	17

#	ARTICLE	IF	CITATIONS
19	Structural Comparison of Enterococcus faecalis and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities. <i>Molecules</i> , 2019, 24, 1257.	3.8	17
20	Identification of the Binding Modes of N-Phenylphthalimides Inhibiting Bacterial Thymidylate Synthase through X-Ray Crystallography Screening. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5454-5467.	6.4	13
21	Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. <i>Scientific Reports</i> , 2016, 6, 27198.	3.3	10
22	2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes. <i>European Journal of Medicinal Chemistry</i> , 2014, 75, 169-183.	5.5	9
23	2-Deoxyuridine 5-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9356-9360.	6.4	8
24	Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9011-9033.	6.4	8
25	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7374-7380.	6.4	6
26	Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth. <i>Molecules</i> , 2019, 24, 3493.	3.8	4
27	Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors. <i>Molecules</i> , 2019, 24, 1362.	3.8	2
28	Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases. <i>Pharmaceuticals</i> , 2021, 14, 1246.	3.8	2